Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ARAV | Common Stock | Options Exercise | $741 | +12.4K | +1.31% | $0.06 | 954K | Nov 30, 2021 | Direct | F1 |
transaction | ARAV | Common Stock | Options Exercise | $9.3K | +38.8K | +4.06% | $0.24 | 993K | Nov 30, 2021 | Direct | F2 |
transaction | ARAV | Common Stock | Options Exercise | $120 | +500 | +0.05% | $0.24 | 993K | Nov 30, 2021 | Direct | F3 |
transaction | ARAV | Common Stock | Sale | -$811 | -252 | -0.03% | $3.22* | 993K | Nov 30, 2021 | Direct | F4 |
transaction | ARAV | Common Stock | Sale | -$9.51K | -2.95K | -0.3% | $3.22* | 990K | Nov 30, 2021 | Direct | F4 |
transaction | ARAV | Common Stock | Sale | -$126 | -39 | 0% | $3.22* | 990K | Nov 30, 2021 | Direct | F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ARAV | Stock Option | Options Exercise | $0 | -12.4K | -100% | $0.00* | 0 | Nov 30, 2021 | Common Stock | 12.4K | $0.06 | Direct | F1 |
transaction | ARAV | Stock Option | Options Exercise | $0 | -38.8K | -100% | $0.00* | 0 | Nov 30, 2021 | Common Stock | 38.8K | $0.24 | Direct | F2 |
transaction | ARAV | Stock Option | Options Exercise | $0 | -500 | -5.48% | $0.00 | 8.62K | Nov 30, 2021 | Common Stock | 500 | $0.24 | Direct | F3 |
Id | Content |
---|---|
F1 | On November 14, 2012, Reporting Person was granted an option to purchase 32,500 shares of the common stock of Aravive at an exercise price of $0.02 per share. Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018 (the "Merger Agreement"), this option was converted into an option to purchase 12,350 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. |
F2 | On October 1, 2014, Reporting Person was granted an option to purchase 102,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,761 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. |
F3 | On December 31, 2014, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger. |
F4 | This transaction represents the sale of stock to cover the exercise price of the options. |